source
- Merck's efinopegdutide shows strong MASH resolution in phase 2b trialMerck & Co. reported results from a phase 2b trial (MK-6024-013) evaluating efinopegdutide, a GLP-1 and glucagon receptor co-agonist, in patients with metabolic dysfunction-associated steatohepatit…
- Rivia unveils AI-driven DataFindings module to accelerate clinical trial data cleaning, Scancell adopts earlySwiss CRO Rivia introduced an AI-powered DataFindings module that integrates with its Rivia Core platform to automate continuous review of clinical trial data. The tool uses AI agents to help user…